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ABSTRACT
Clerocidin (CL), a microbial diterpenoid, reacts with
DNA via its epoxide group and stimulates DNA cleav-
age by type II DNA topoisomerases. The molecular
basis of CL action is poorly understood.We establish
by genetic means that CL targets DNA gyrase in the
Gram-positive bacterium Streptococcus pneumo-
niae, and promotes gyrase-dependent single-
and double-stranded DNA cleavage in vitro. CL-sti-
mulated DNA breakage exhibited a strong prefer-
ence for guanine preceding the scission site
(1 position). Mutagenesis of 1 guanines to A, C
or T abrogated CL cleavage at a strong pBR322
site. Surprisingly, for double-strand breaks, scission
on one strand consistently involved a modified
(piperidine-labile) guanine and was not reversed by
heat, salt or EDTA, whereas complementary strand
scission occurred at a piperidine-stable 1nt and
was reversed by EDTA. CL did not induce cleavage
by amutant gyrase (GyrA G79A) identified here in CL-
resistant pneumococci. Indeed, mutations at G79
and at the neighbouring S81 residue in the GyrA
breakage-reunion domain discriminated poisoning
by CL from that of antibacterial quinolones. The
results suggest a novel mechanism of enzyme inhibi-
tion in which the1nt at the gyrase-DNA gate exhibit
different CL reactivities to produce both irreversible
and reversible DNA damage.
INTRODUCTION
Clerocidin (CL) (Figure 1) is a cytotoxic diterpenoid nat-
ural product (1) that inhibits bacterial DNA gyrase and
mammalian DNA topoisomerase II (2,3). Unlike other
topoisomerase poisons, CL induces an irreversible DNA
break when guanine (G) is present at the 1 position from
the cleavage site (3–5). In the absence of topoisomerases,
CL itself exhibits an intrinsic DNA alkylating activity
against guanines that are exposed in single-stranded
DNA regions, promoting spontaneous depurination and
subsequent DNA scission at the abasic site (6). These
observations and other data suggest that mammalian
type II topoisomerases potentiate CL attack at guanines
that have in some way been ‘processed’ in the enzyme-
DNA complex (5,6). Thus, although toxicity has pre-
cluded clinical use, CL is of interest as a probe of the
normally transient cleavage complex formed in the reac-
tion cycle of type II topoisomerases.
Recent work has focused on the structural features
of CL and DNA necessary for intrinsic- and mammalian
topo II-mediated DNA cleavage. Both reactions require
the highly strained epoxide moiety in the C12–C16 region
(6,7) (Figure 1): opening of the epoxide ring by prolonged
incubation with ethanol abolishes drug activity. CL reacts
very slowly with duplex DNA (requires 24–48 h) but more
rapidly with single-stranded DNA producing irreversible
cleavage at G and C (7,8). The epoxide ring reacts cova-
lently with the N-7 position of guanine resulting in facile
release of the modiﬁed base (7). The aldehyde linked to
C4 is not essential as related epoxy antibiotics such as
terpentecin and UCT4B lack the moiety yet retain activity
(3,9). The diterpenoid ring system is dispensable for intrin-
sic alkylating activity and can be replaced by naphthalene
(7). Unlike the intrinsic reaction with duplex DNA, topo
II-mediated cleavage induced by CL is rapid (complete in
minutes) and occurs irreversibly at guanines but with one-
third of DNA scission sites occurring reversibly at cyto-
sines (5). It is known that the reactive NH2 and N3 sites of
cytosine are involved in base pairing and are thereby pro-
tected from CL alkylation. Therefore, the C preference
presumably arises from non-covalent interaction of CL
with the enzyme–DNA complex in a manner akin to clas-
sical topo II poisons (8). These features reinforce the idea
that the conformation of bound DNA in the topoisome-
rase complex has a major inﬂuence on CL action.
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Indeed, substantial distortion of nicked duplex DNA
bound to yeast topo II has recently been observed by
X-ray crystallography (10).
CL is potentially an interesting probe of bacterial type
II topoisomerases. Thus, although gyrase and topo IV
share structural and mechanistic similarities, they manip-
ulate DNA in distinct ways to produce diﬀerent DNA
products (11–15). Gyrase, an GyrA2GyrB2 complex speci-
ﬁed by gyrA and gyrB genes, introduces negative super-
coils into DNA and has important roles in maintaining
bacterial chromosome supercoiling and in the initiation
and elongation phases of DNA replication. Topo IV, a
ParC2ParE2 tetramer, encoded by parC and parE genes,
preferentially relaxes positively supercoiled DNA and
unlinks pre-catenanes and catenated chromosomes
formed during DNA replication. Both enzymes act by
passing a duplex DNA segment through a transient
enzyme–DNA break formed by the covalent cleavage
complex (14,16,17). Whereas for topo IV, DNA scission
occurs in a 34-bp DNA ‘gate’ segment (18), gyrase wraps a
150-bp DNA segment that contains both the ‘gate’ and
‘transported’ DNA segments (19–21). It is not known
whether DNA wrapping by gyrase (and its absence in
the topo IV complex) aﬀects base potentiation and CL
action.
Although CL studies have concentrated on mammalian
topo II, the drug does have antibiotic activity against
Escherichia coli and particular potency against Gram-
positive species such as Staphylococcus aureus (2,3).
Initial work reported that CL inhibits gyrase (from
E. coli) (2), which is also the target of antibacterial quino-
lone poisons in Gram-negative bacteria. Recently, we
showed that CL inhibits puriﬁed recombinant S. pneumo-
niae topo IV to produce irreversible DNA scission at 1G
and on that basis proposed that topo IV is the CL target
in Gram-positive bacteria (22), as it is for many
quinolones (23). In the present study, we have determined
the target of CL in S. pneumoniae, a Gram-positive system
amenable to genetic manipulation through its ability to
undergo DNA transformation. Contrary to our previous
suggestion (22), we ﬁnd that gyrase is the primary target. In
complementary biochemical experiments, we show that CL
traps gyrase cleavage complexes on DNA, and we explore
fully the unusual chemical, DNA and protein requirements
for this reaction. This study is the ﬁrst to demonstrate that
CL diﬀerentially modiﬁes each half of a topoisomerase-
DNA gate, and new data reported here illuminates key
diﬀerences in CL action versus antibacterial quinolone poi-
sons both in vivo and in vitro.
MATERIALS AND METHODS
Bacterial strains, reagents and plasmids
Streptococcus pneumoniae 7785 is a ciproﬂoxacin-
susceptible clinical strain isolated at St George’s
Hospital Medical School (24). The strain and its deﬁned
quinolone-resistant mutants (25) were grown either on
brain heart infusion-agar plates containing 10% horse
blood or in liquid culture in Tryptic Soy Broth (TSB)
(Difco). Streptococcus pneumoniae R6, a standard labora-
tory strain competent for genetic transformation, and
E. coli strain BL21(DE3)pLysS were from our laboratory
collection. TOPO10 competent cells were from Invitrogen.
CL, a gift from Leo Pharmaceutical Products (Ballerup,
Denmark), was prepared as a 5-mg/ml stock solution
in DMSO, stored frozen at 808C and used within 4
weeks. Competence stimulating peptide was synthesized
by Activotec, Cambridge, UK. Supercoiled and relaxed
pBR322 were purchased from New England Biolabs
and John Innes Enterprises, respectively. [g-33P]ATP
(3000Ci/mmol) was from GE Healthcare.
Selection of CL-resistant S. pneumoniaemutants
A culture of S. pneumoniae 7785 was grown in TSB at
378C to an OD600 of 0.8 (about 5 108 cfu/ml). Bacteria
from one millilitre of culture were spun down, plated on
CL-BHI blood plates and incubated aerobically at 378C
for 20 h. Drug challenge at 0.8, 1.6 and 3 mg/ml allowed
recovery of mutants CL6, CL7, CL8 and CL9, mutant
CL10, and mutants CL11, CL12 and CL13, respectively.
The minimum inhibitory concentrations (MICs) of the
mutants for CL were determined by the 2-fold dilution
method (25). Brieﬂy, 105 colony forming units of bac-
teria was spotted on agar plates made up with brain heart
infusion medium supplemented with 10% horse blood and
containing serial 2-fold dilutions of drug. Plates were
examined for growth after overnight aerobic incubation
at 378C. The known ciproﬂoxacin and gemiﬂoxacin
MICs of strain 7785 were determined in parallel as a con-
trol (26). The eight mutants all exhibited a CL MIC of
12 mg/ml and a ciproﬂoxacin MIC of 1 mg/ml. For parent
strain 7785, the MICs for CL, ciproﬂoxacin and gemiﬂox-
acin were 0.2, 1 and 0.06 mg/ml, respectively.
Figure 1. Chemical structure of CL.
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DNA sequence analysis of topoisomerase genes
in resistant mutants
To obtain S. pneumoniae genomic DNA, strain 7785 and
its drug-resistant mutants were grown in 10ml of TSB
broth to an OD600 of 0.6 and harvested by centrifugation.
The bacterial pellet was re-suspended in 2ml of 50mM
Tris–HCl, pH 7.5, 10mM EDTA. SDS and proteinase
K were added to ﬁnal concentrations of 1% and
100 mg/ml, respectively and the suspension was incubated
at 428C for 1 h. Phenol extraction was performed twice,
the DNA was recovered by ethanol precipitation and
redissolved in Tris–HCl, pH 7.5, 1mM EDTA. Genomic
DNA from strain CL12 was used as a template to amplify
the gyrase and topo IV genes using Taq DNA polymerase.
PCR was performed for 30 cycles: denaturation at 938C
for 45 s, annealing at 528C for 45 s and ampliﬁcation at
748C for 3min. Full-length genes were ampliﬁed using the
following primer pairs: VGA35/VGA36 for gyrA, P7164/
P7165/for gyrB, N6894/VPC2 for parC and N7043/7044
for parE (27). Automated sequence analysis of each PCR
product was done by Lark Technologies, Inc employing a
series of nested primers complementary to the ampliﬁed
DNA. The four gene sequences from CL12 (totalling
nearly 9 kb) were compared with those of the parent
S. pneumoniae 7785 (27). The gyrase and topo IV genes
of three other randomly chosen mutants CL10, CL11 and
CL13 were also sequenced.
Genetic transformation of S. pneumoniae
The 2.4-kb gyrA gene was ampliﬁed by PCR from parent
strain S. pneumoniae 7785 and CL-resistant mutant CL12
using primers VGA35/VGA36 (27) and used to transform
S. pneumoniae strain R6 following the approach of Pozzi
et al. (28). Brieﬂy, S. pneumoniae R6 was grown in tryptic
soy broth (TSB, Difco) and 30min before onset of sta-
tionary phase, cultures were frozen in 10% glycerol.
Competence medium (TSB pH 8.0, 10% glycerol, 0.16%
bovine serum albumin, 0.01% CaCl2) (10ml) was mixed
with 0.5ml of thawed R6 cell stock. Competence stimulat-
ing peptide was then added to 100 ng/ml along with trans-
forming DNA (ﬁnal concentration 1 mg/ml). The cell mix
was incubated at 378C for 2.5 h and then plated on TSB-
agar plates containing CL at 0.8, 1.6 and 3 mg/ml, respec-
tively. Plates were incubated aerobically at 378C for 48 h.
CL-resistant colonies were obtained by transformation
with CL12 gyrA DNA but not with the 7785 gyrA
DNA. The gyrA genes of ﬁve randomly chosen CL-
resistant R6 transformants were sequenced in full and
the antibiotic susceptibiliy of the strains was determined
by the 2-fold dilution method. All ﬁve mutants exhibited
a CL MIC of 12–24 mg/ml, compared with an MIC
0.2–0.4mg/ml for the recipient R6 strain. The ciproﬂoxacin
MIC of the transformants was the same as for R6, i.e.
0.5mg/ml.
Recombinant gyrase and topo IV subunits
Streptococcus pneumoniae GyrA, GyrB, ParC, ParE and
GyrA S81F were expressed as His-tagged proteins in
E. coli from plasmids pXP10, pXP9, pXP13, pXP14 and
pXP15, respectively, and were puriﬁed to >95% homoge-
neity as described previously (27,29). GyrA G79A and
GyrA G79D were prepared by expression from gyrA plas-
mid pXP10 whose gyrA codon 79 had been altered using
the QuikChange Site-Directed Mutagenesis Kit
(Stratagene) according to the manufacturer’s protocol.
The mutagenic primers used for PCR to obtain gyrA
(G79A) were 50GGT-AAA-TAT-CAC-CCA-CAC-GCG-
GAT-TCC-TCT-ATT-TAT-GAA (nucleotide positions
217–255, altered nucleotide 237 is underlined) and its
complement, 50TTC-ATA-AAT-AGA-GGA-ATC-CGC-
GTG-TGG-GTG-ATG-TTT-ACC. For gyrA (G79D),
the same forward primer was made except nucleotides
C237 and G238 were replaced with A and C, respectively.
The appropriate complementary changes were introduced
into the reverse primer. The mutant gyrA genes were
sequenced in full to conﬁrm the presence of the single
desired mutation at codon 79. The mutant GyrA proteins
were expressed in E. coli and puriﬁed by Ni–agarose chro-
matography as described previously for wild-type GyrA
(27). When induced and puriﬁed under identical condi-
tions, GyrA, GyrA S81F and GyrA G79A showed similar
speciﬁc activities in a standard DNA supercoiling assay
(27) of 5 104 U/mg: the speciﬁc activity of the GyrA
G79D protein was 2.5 104U/mg.
Mutagenesis of specific DNA cleavage sites
Our mapping studies (see below) identiﬁed a strong site
of gyrase cleavage site at 1073 in pBR322 whose sequence
is known in full (30). Mutant sites bearing alterations at
1073 and at 1078 on the complementary strand were gen-
erated from pBR322 using complementary primers in the
QuikChange Mutagenesis Kit according the manufac-
turer’s instructions. Three forward primers were made
50CTGTCCAGGCAGGTAGATXACGAYCATCAGG
GACAGCTTCAA (nucleotide position 1055–1096) in
which positions G1073 and C1078 (marked by X and Y)
were pair-wise replaced with A and T, C and G or T and
A, respectively. Three reverse primers were designed to
complement the altered sequences. Mutated plasmids
were recovered and the introduction of site changes was
conﬁrmed by DNA sequence analysis.
A similar approach was used to mutate the ‘E’ cleavage
site for topo IV found in the S. pneumoniae parE gene (31).
This site was shown to be eﬃciently cleaved by topo IV in
the presence of gemiﬂoxacin and therefore ideal for muta-
tional studies (31) Three mutagenic forward primers were
created i.e. 50TACCAAGGTCATGAAXGACTYTGCA
CGTAAAACAGGTCTTCT-30 (parE nucleotide posi-
tions 882 to 923) in which T897 and A902 (denoted by
X and Y) were substituted pair-wise with G and C, C and
G and A and T. Three complementary (reverse) primers
were made accordingly. Plasmid pXP1 carrying the E site
was used as template for PCR mutagenesis. Mutations at
the E site were conﬁrmed by DNA sequence analysis of
recovered plasmids.
5’-end labelling of primers and DNA cleavage substrates
Oligonucleotide primers (30 pmol) were labelled at their 50
end by incubation with [g-33P] ATP (30 pmol) and T4
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polynucleotide kinase. The mixture was incubated at 378C
for 30min followed by heat inactivation at 908C for 3min.
The labelled primers were used in PCR to generate cycle
sequencing chain termination ladders and to amplify
DNA fragments speciﬁcally labelled at one or the other
50 end. A 290-bp product, the ‘S fragment’ internal to
S. pneumoniae parE (nucleotides 1179–1468) was ampliﬁed
from plasmid pXP1 using primers S6398 and S6399 as
described earlier (31). Similarly, 295-bp (nucleotides
905–1200) and 234-bp (966–1200) fragments were ampli-
ﬁed from pBR322 using primers 50Gyra (pBR905) and
Apbr1200 (pBR1200), and pBR966 and pBR1200, respec-
tively (31). A 256-bp E fragment from S. pneumoniae parE
(containing the strong E cleavage site for topo IV) was
ampliﬁed from pXP1 using primers EFOR and EREV
(31). To label one or other strand, PCR was set up with
10 pmol of 50-end 33P-labelled forward primer plus an
equal amount of the unlabelled reverse primer. DNA frag-
ments were puriﬁed with the QIAquick PCR puriﬁcation
kit (Qiagen, CA). The same procedures were used to gen-
erate PCR products carrying mutated versions of the
strong pBR322 site and of the E site.
DNA supercoiling and DNA cleavage assays
DNA gyrase activity was examined in the standard DNA
supercoiling assay (27) using a reaction buﬀer containing
35mM Tris–HCl, pH 7.5, 6mMMgCl2, 1.8mM spermi-
dine, 24mMKCl, 5mM DTT, relaxed pBR322 (0.4 mg),
36 mg/ml BSA, 6.5% glycerol (w/v), 1.4mM ATP. Wild-
type and mutant gyrase activities were reconstituted from
appropriate GyrA and GyrB subunits. Subunit speciﬁc
activity was determined by serial dilution and assay in
the presence of a 5-fold excess of the complementing sub-
unit (to activate all the available limiting subunit).
For cleavage of supercoiled DNA, gyrase (0.45 mgGyrA
and 1.7 mgGyrB) was incubated with supercoiled pBR322
DNA (0.4 mg) in the absence or presence of CL or cipro-
ﬂoxacin in gyrase supercoiling buﬀer from which ATP had
been omitted. After 1-h incubation at 378C, SDS and pro-
teinase K were added to ﬁnal concentrations of 1% and
100 mg/ml, respectively, and incubation was continued for
another hour at 428C. Loading buﬀer was added to the
samples and DNA products were separated by electro-
phoresis in 1% agarose in TBE buﬀer (90mM Tris base,
90mM boric acid, 2.5mM EDTA) prior to ethidium bro-
mide staining and photography under UV light using an
Alpha Innotech digital camera. The same protocol was
used to study cleavage of short unlabelled PCR fragments
(200–300 bp) except inclusion of ATP was required for
eﬃcient breakage and reaction products were separated
on 2.5% low-gelling temperature agarose in TBE buﬀer.
Cleavage of end-labelled DNA substrates was carried
out in DNA supercoiling assay buﬀer. The mixture
(20 ml) contained 300 fmol end-labelled DNA substrate,
2 mg of GyrA and 4 mg of GyrB proteins, 1mM ATP,
and 200 mM CL or 100 mM gemiﬂoxacin. After incubation
for 1 h at 378C, samples were treated with SDS and pro-
teinase K as described for non-radioactive substrates,
divided into two equal aliquots and precipitated with etha-
nol. One dried aliquot of each sample was taken up in
100 ml of 1-M piperidine, heated at 908C for 30min (to
release any modiﬁed bases) and the piperidine was
removed under vacuum. DNA samples (treated and
untreated with piperidine) were taken up in formamide
gel loading buﬀer (32% formamide, 3.3mMNaOH,
0.085% bromophenol blue, 0.085% xylene cyanol) and
heated at 908C for 2–4min. The DNA products were sepa-
rated by electrophoresis in a denaturing 6% polyacryla-
mide gel alongside an appropriate chain termination
sequencing ladder (obtained with the Fmol DNA cycle
sequencing kit) and/or a G+A ladder generated by the
Maxam–Gilbert method (32). Gels were dried under
vacuum on to Whatmann 3MM ﬁlter paper, exposed to
a PhosphorImager screen, and visualized using software
from Amersham Biosciences and ImageQuant.
RESULTS
DNA gyrase is the target of CL in S. pneumoniae
As a ﬁrst step in understanding CL action, we examined
its activity against wild-type S. pneumoniae strain 7785
alongside clinically important quinolones. CL was a
potent inhibitor with a minimum inhibitory concentration
of 0.2mg/ml (0.6 mM), which compares favourably with
values of 0.06 (0.12 mM) and 1–2mg/ml (3–6 mM) for gemi-
ﬂoxacin and ciproﬂoxacin, respectively (26). Mutants of
S. pneumoniae 7785 resistant to CL were obtained in a
single step by plating on agar containing various inhibi-
tory levels of the drug. Mutant CL12 was 60-fold less
susceptible to CL but remained fully susceptible to cipro-
ﬂoxacin. DNA sequence analysis revealed a novel gyrA
mutation (GGG to GCG, G79A) with no other changes
in gyrA or gyrB, or in the topo IV parC and parE genes.
The same gyrA mutation was present in three other ran-
domly chosen mutants selected independently at diﬀerent
drug levels. Repeated recovery of the same gyrA mutation
in several single-step CL-resistant mutants implicates
gyrase in CL action in vivo.
To show conclusively that gyrase is the primary target
of CL in S. pneumoniae, we used genetic transformation to
reintroduce the gyrA (G79A) mutation into a CL-suscep-
tible S. pneumoniae strain and examined the CL suscept-
ibility of the transformants. For these experiments,
we ampliﬁed just the gyrA(G79A) gene of mutant CL12
as a 2.4-kb DNA fragment and used it to transform
S. pneumoniae strain R6, which (unlike 7785) is competent
to undergo genetic transformation by uptake of donor
DNA and chromosomal integration by homologous
recombination (28). Using the gyrA (G79A) gene as
donor DNA, CL-resistant transformants were readily
recovered on CL-agar plates: about 0.02% of the recipient
R6 cells became transformed, i.e. very much higher than
the observed frequency of spontaneous mutants (10–8).
No transformants were obtained using as a control the
wild-type gyrA gene from the parental 7785 strain. The
gyrA genes of ﬁve randomly chosen transformants were
ampliﬁed by PCR and sequenced in full. Each carried the
G79A codon change (G to C at position 236). Moreover,
the gyrA genes exhibited mosaic polymorphism for silent
nucleotide changes indicative of uptake/integration of
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donor CL12 gyrA, i.e. at position 225 (C to T, 5 of 5
transformants), 264 (C to T, 4 of 5 transformants) and
at 141 (C to T, one of ﬁve transformants). Therefore,
the resistant colonies were genuine transformants and
not spontaneous mutants. Crucially, all ﬁve transformants
exhibited a CL MIC of 12–24mg/ml (the same as strain
CL12) versus 0.2–0.4 mg/ml for the recipient R6 strain and
(like CL12) all remained susceptible to ciproﬂoxacin.
It appears that the gyrA (G79A) mutation alone can
account for the 60-fold increase in CL resistance (seen
for CL12) and that gyrase is the primary target of the
drug in S. pneumoniae.
CL promotes gyrase cleavage of supercoiled DNA
Given the outcome of the genetic experiments, we tested
the eﬀects of CL on S. pneumoniae gyrase in catalytic and
DNA cleavage assays (Figure 2). As a control, we
employed ciproﬂoxacin, a ﬂuoroquinolone often used as
a comparator for inhibition/cleavage studies. In the
absence of drug (Figure 2A, lanes 0), gyrase converted
relaxed plasmid DNA (lane b) into the supercoiled form
in an ATP-dependent reaction. CL inhibited this activity
in a dose-dependent fashion with 50% inhibition (IC50)
at 40 mM, i.e. comparable to the ciproﬂoxacin IC50 of
80 mM (Figure 2A, compare left and right lanes).
For the DNA cleavage assay, supercoiled pBR322 was
incubated with gyrase in the absence or presence of CL or
ciproﬂoxacin at concentrations up to 160 mM. DNA clea-
vage was induced by addition of SDS and, after proteinase
K treatment, the DNA was separated and displayed by
agarose gel electrophoresis (Figure 2B). There was little
or no enzyme-induced DNA breakage in the absence of
drug (lanes 0) but addition of CL (or ciproﬂoxacin) caused
a dose-dependent production of both nicked and linear
DNA corresponding to the capture of single-stranded
and double-stranded DNA breaks, respectively
(Figure 2B). Digital quantitation of DNA bands showed
that CL induced 25% linearization of input DNA (CC25)
at 20–40 mM compared with a value of 20 mM for cipro-
ﬂoxacin (Figure 2B).
ATP stimulation and sequence specificity of DNA breakage
The speciﬁcity of gyrase-mediated DNA breakage pro-
moted by CL was examined using the 50-end 33P-labelled
S fragment from the S. pneumoniae parE gene and com-
pared to that of gemiﬂoxacin, an anti-pneumococcal qui-
nolone whose induction of sequence-speciﬁc cleavage has
been studied in detail for pneumococcal gyrase and topo
IV (31). Cleavage of TOP and BOTTOM DNA strands by
both drugs was markedly enhanced by the inclusion of
ATP and required the presence of gyrase: no breakage
was seen with CL alone consistent with the known poor
reactivity of CL toward duplex DNA (Figure 3,
Introduction section). CL stimulated a unique repertoire
of cuts, though some sites were also cleaved with gemiﬂox-
acin (Figure 3). Quinolones are known to stabilize
DNA cleavage fragments that possess 30 OH ends and
hence co-migrate with chain termination DNA
sequencing products (21,31). CL-generated fragments
also co-migrated with dideoxy sequencing products
(and some quinolone-stimulated fragments) (Figure 3
and later Figures 4–6) allowing their mapping at the
sequence level. CL-induced gyrase scission occurred
either at single sites or more frequently in pairs on com-
plementary strands showing the characteristic 4-bp stagger
expected of double-stranded DNA breakage by gyrase
(31). A compilation of sites mapped in the pneumococcal
S fragment or plasmid pBR322 (see below) showed a
strong preference for guanine at the 1 position or the
equivalent C at +5 (Table 1). Ten sites of double-stranded
DNA cleavage had both 1G and +5C, i.e. guanine at
both 1 positions. This is the ﬁrst sequence analysis of
CL-promoted cleavage by gyrase.
Selective DNAmodification and cleavage irreversibility
at the DNA gate
In the absence of topoisomerases, it is known that the
epoxide moiety of CL reacts at N-7 of unpaired guanines
(6). Incubation over extended times (24–48 h) leads to loss
of the N-7 alkylated base and strand scission at the abasic
site, a process used in the Maxam–Gilbert DNA sequen-
cing protocol and facilitated by hot piperidine (32). To
determine whether CL modiﬁes bases exposed in the
gyrase cleavage complex, we compared the mobility of
cleavage products from the TOP and BOTTOM strands
of the S fragment (Figure 4A) before (lanes 3) and after
hot piperidine (lanes 4). A number of fragments (denoted
by ﬁlled circles on Figure 4A) suﬀered a 1-nt shift
in mobility after hot piperidine consistent with the loss
of a modiﬁed nucleotide at their extreme 30 end, i.e.
the nucleotide at 1. After hot piperidine, these fragments
co-migrated with the Maxam–Gilbert ladder which have 30
phosphate termini, Shifted fragments invariably arose
from scission at 1G and their production could not be
reversed with salt, EDTA or high temperature (Figure 4A,
lanes 5–7). However, the mobility of other cleavage frag-
ments (denoted by open circles in Figure 4A) was not
aﬀected by hot piperidine (lanes 3 and 4). These fragments
arose from cleavage at sites with A, C, T or even G at 1,
and invariably their production could be at least partially
reversed with EDTA (lanes 6), though not with salt or
heat (lanes 5 and 7). Control experiments showed that
gemiﬂoxacin-promoted cleavage products were universally
unaﬀected by piperidine consistent with the known non-
covalent interaction of quinolones with the cleavage com-
plex (lanes 8 and 9). Moreover, cleavage by gemiﬂoxacin
(lane 8), a high-aﬃnity quinolone (26), was partially
reversed with high salt (lane 10) and fully reversed with
EDTA and heat (lanes 11 and 12), consistent with sealing
of unmodiﬁed 30 OH breaks. Thus, in contrast to quino-
lones, it appears that CL stimulates both irreversible and
reversible gyrase cleavage of the S fragment with evidence
of covalent modiﬁcation at some guanine sites.
Reversible and irreversible DNA scission by CL with
covalent modiﬁcation at some sites was also seen using
a diﬀerent DNA substrate, namely a PCR product ampli-
ﬁed from plasmid pBR322 (nucleotides 966–1200) and
50-33P end-labelled in the TOP or BOTTOM strands
(Figure 5A).
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Access to data from both strands of the S fragment and
of the pBR322 fragment, enabled us to examine the link
between guanine modiﬁcation and irreversibity/reversibil-
ity at both 1 positions for a number of double-stranded
gyrase breakage sites. The results are summarized for each
fragment in Figures 4B and 5B, which bring out a novel
and previously unreported feature. In fact, all the sites
show evidence of diﬀerential CL attack, namely complete
guanine modiﬁcation and irreversible cleavage on one
strand (ﬁlled arrowhead and circle) is invariably accom-
panied by reversible cleavage at a wholly (or partially)
unmodiﬁed nucleotide on the complementary strand
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Figure 2. CL inhibits DNA gyrase and stimulates enzyme-mediated DNA cleavage. (A) Inhibition of DNA supercoiling by DNA gyrase. Relaxed
pBR322 DNA was incubated with S. pneumoniae gyrase (1U) and 1.4mM ATP in the absence or presence of CL or the quinolone ciproﬂoxacin
(CIP) at the concentrations indicated on the ﬁgure. Reaction mixtures were loaded on a 1% agarose gel and DNA bands were visualized by staining
with ethidium bromide and uv light. Lane a, supercoiled pBR322 (SC); lane b, relaxed pBR322 (R). (B) Stimulation of gyrase-mediated DNA
breakage. Supercoiled pBR322 was incubated at 378C for 1 h with gyrase (in the absence of ATP) with CL or CIP at the concentrations indicated on
the ﬁgure. After addition of SDS and incubation with proteinase K, DNA products were separated and displayed by electrophoresis in 1% agarose.
(Lane a) is the input supercoiled pBR322, (lane b) is pBR322 linearized with EcoRI. N, L and SC denote nicked, linear and supercoiled plasmid
DNA, respectively. In (A) and (B), gel images were captured using an Alpha Innotech digital camera and DNA bands were quantitated and analysed
using associated software.
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(open arrowhead and circle). When the second 1 nt was
A, C or T, there was no detectable piperidine-sensitive
modiﬁcation, and DNA scission was wholly reversible at
this position. However, sites with two 1G nucleotides
(e.g. the major pBR322 site in Figure 5) showed complete
guanine modiﬁcation on one strand accompanied on
the second strand by partial guanine modiﬁcation
(0–60% shift to smaller fragment with hot piperidine
depending on the site) and at least partial reversibility.
Evidently, CL reacts diﬀerentially at the two 1 positions
of the gyrase–DNA gate, even when both nucleotides are
guanines.
Mutagenesis establishes CL preference for1G
The role of the 1 nt in CL action was further investigated
using directed mutagenesis of the major pBR322 gyrase
site at 1073, a site bearing G at both 1 positions
(Figure 5B) and which was cleaved some 10 more eﬃ-
ciently than other sites, e.g. in the S fragment. Given that
sites exhibiting a single 1G can be cleaved (Table 1,
Figures 4B and 5B), we constructed mutants of the
pBR322 site in which both 1 positions (G1073 and com-
plementary strand G1078) were altered to either A, C or T
nucleotides. The sites, contained in end-labelled 295-bp
PCR products, were used as cleavage substrates for
gyrase in the presence of gemiﬂoxacin or CL, and the
products were displayed on a denaturing polyacrylamide
gel (Figure 6). Gemiﬂoxacin promoted eﬃcient double-
stranded DNA cleavage at the wild-type (WT) site and
its 1A, 1C and 1T mutants (lanes 1) producing the
expected fragment (circles in Figure 6), thereby showing
that the mutant sites are still recognized by gyrase. CL
induced cleavage at the WT site to produce a DNA frag-
ment that co-migrated with the gemiﬂoxacin-stabilized
fragment and with the appropriate dideoxy DNA
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Figure 3. CL-promoted DNA cleavage mediated by gyrase occurs at speciﬁc sites and is stimulated by ATP. The 290-bp S fragment (from the
S. pneumoniae parE gene) 33P-labelled at the 50 end of the TOP or BOTTOM strand was cleaved by S. pneumoniae gyrase in the absence or presence
of 200 mM CL or 100 mM gemiﬂoxacin (Gemi) and 1mM ATP. These drug concentrations were chosen so as to achieve comparable cleavage levels of
the linear DNA substrate. DNA products were separated by electrophoresis in a denaturing 6% polyacrylamide gel alongside DNA sequencing
products (ACGT) obtained by the chain termination method using the same 50-labelled oligonucleotide primers employed in PCR.
5522 Nucleic Acids Research, 2008, Vol. 36, No. 17
sequencing product (WT, lanes 1 and 2). However, this
fragment was absent for CL cleavage of the mutant
1A, 1C and 1T substrates (lanes 2). Instead,
enhanced cleavage was seen at nearby sites i.e. 30 of
G1079 (smaller fragment) and G1075 (larger fragment)
(Figure 6, 1A, 1C and 1T, lanes 2) and both frag-
ments exhibited a one-base shortening on piperidine treat-
ment (lanes 3). These mutagenesis data provide the ﬁrst
direct evidence that CL-induced gyrase cleavage of DNA
is prevented when G is absent from both 1 positions.
Protein requirements for poisoning: role of GyrA G79
and S81
In contrast to theDNA substrate, very little is known about
the enzyme interactions that govern CL activity. The iden-
tiﬁcation of a novel gyrA mutation (G79A) conferring
CL-resistance in S. pneumoniae is therefore of considerable
interest. The mutation aﬀects a conserved glycine residue
that lies in the CAP-like helix–turn–helix motif of GyrA
thought to bind DNA (33,34). A diﬀerent mutation
of the equivalent glycine residue (to aspartate or cysteine)
has been associated (albeit rarely) with clinical resistance to
quinolones in E. coli (35,36). Moreover, in S. pneumoniae,
adjacent mutations in GyrA of S81 to F or Y commonly
cause resistance to quinolones (25,29,37) implying that a
localized region of GyrA is implicated in binding diﬀerent
gyrase poisons. To understand better how CL interacts to
poison gyrase, we expressed the S. pneumoniaeG79A, S81F
andG79Dmutant GyrA subunits inE. coli and puriﬁed the
proteins to homogeneity. In a supercoiling assay, the three
mutant proteins reconstituted a gyrase activity comparable
to that of the wild-type enzyme (Figure 7A, see ref. 29 for
GyrA S81F data).
Unlike the equipotent DNA cleavage promoted by CL
and ciproﬂoxacin with WT gyrase (Figure 2B), enzyme
reconstituted with GyrA G79A induced cleavage of super-
coiled pBR322 strongly with ciproﬂoxacin but only
weakly with CL (Figure 7B). These biochemical data
agree with our genetic studies showing that the GyrA
G79A alteration accounts for the CL-resistant but cipro-
ﬂoxacin-sensitive phenotype of the S. pneumoniae CL12
mutant. Conversely, gyrase reconstituted with GyrA
S81F promoted DNA cleavage with CL but not with
ciproﬂoxacin (Figure 7C). This result is in accord with
data showing that quinolone-resistance mutations in
gyrase or topo IV conferred no bacterial cross resistance
to CL (GyrA S81F, ParC S79F) or mild (2- to 4-fold)
hypersensitivity (GyrA S81Y, ParC S79Y) (Pan,X.S. and
Fisher,L.M., unpublished data). Finally, even though very
active in DNA supercoiling (Figure 7A), the GyrA G79D
complex did not induce DNA cleavage with either CL or
ciproﬂoxacin even at 320 mM (Figure 7D). The responses
of the mutant gyrases in ATP-independent plasmid clea-
vage were reproduced in ATP-dependent cleavage of end-
labelled DNA (Pan,X.S. and Fisher,L.M., unpublished
data). It appears that the sidechains of residues 79 and
81 in GyrA are a critical determinant of whether gyrase
can be poisoned by CL and quinolones.
DISCUSSION
We have shown that CL targets gyrase in the Gram-
positive bacterium S. pneumoniae and induces single-
and double-stranded DNA breakage by the enzyme
in vitro. Using a variety of biochemical approaches,
we demonstrate that gyrase-mediated DNA scission
induced by CL has unusual characteristics including a
preference for guanine bases, diﬀerential nucleotide mod-
iﬁcation, elements of irreversibility and reversibility and
diﬀerences in protein requirements that distinguish it
from enzyme poisoning by antibacterial quinolones. It
appears that CL has a unique antibiotic mechanism that
involves selective chemical inactivation of gyrase-DNA
complexes.
Previously, we showed that CL acts on topo IV to cause
irreversible DNA cleavage at 1G leading to the reason-
able conclusion that topo IV is the intracellular drug
target (22). However, the genetic data presented here
demonstrates that CL primarily targets gyrase in vivo.
Presumably, CL also reacts with topo IV in vivo but the
enzyme is a secondary target. In the earlier work, we did
not have access to genetic evidence and did not know that
gyrase is also potently (and irreversibly) inhibited by the
drug with IC50 and CC25 values (for DNA supercoiling
Table 1. Alignment of DNA cleavage sites for S. pneumoniae gyrase
induced by clerocidin
Sites involving cleavage on complementary DNA strands
1 +5
CCCCAGCC CAAT CTAAGAAT Site 1 S fragment
TAAGAATG AACT CTATCTAG 2 S fragment
AGTTGAGG GGGA CTCTGCCG 3 S fragment
TTGAGGGG GACT CTGCCGGT 4 S fragment
CAAGGTCG TGAC CGCAAGTT 5 S fragment
TTCCAGGC TATT CTACCTCT 6 S fragment
CAGGCTAT TCTA CCTCTTCG 7 S fragment
AGGCTATT CTAC CTCTTCGT 8 S fragment
ATTCTACC TCTT CGTGGTAA 9 S fragment
CCAAGATG GCGG ATATCCTC 10 S fragment
CAAAAATG AAGA GATCAATA 11 S fragment
GGTAGATG ACGA CCATCAGG Site 1 pBR322-1073
GCAGGTAG ATGA CGACCATC 2 pBR322-1070
GTAGATGA CGAC CATCAGGG 3 pBR322
GAGGCTGG ATGG CCTTCCCC 4 pBR322
CGCTTCCG GCGG CATCGGGA 5 pBR322
AGGCCATG CTGT CCAGGCAG 6 pBR322
CATCAGGG ACAG CTTCAAGG 7 pBR322
TTACCAGC CTAA CTTCGATC 8 pBR322
Sites with cleavage on one DNA strand
AGATAGAG TTCA TTCTTAGC Site 12 S fragment
GCCGGTGG TTCT GCCAAACA 13 S fragment
TTTGGCAG AACC ACCGGCAG 14 S fragment
AGCCAAGG CCAA GATGGCGG 15 S fragment
GACCGCTG ATCG TCACGGCG 9 pBR322
CGGAAGCG AGAA GAATCATA 10 pBR322
ATAATGGG GAAG GCCATCCA 11 pBR322
DNA sequences surrounding the breakage point are shown for one
strand of each double-stranded breakage site or for sites of single-
stranded breakage promoted by clerocidin in the parE S fragment
(31) and in pBR322 (905–1200 nt region). The central four nucleotides
(+1 to +4) correspond to those in the 4-bp overhang produced by
DNA breakage by gyrase. Preferred guanines at –1 and cytosines at +5
(indicating guanine at –1 on the complementary strand) are shown in
boldface.
Nucleic Acids Research, 2008, Vol. 36, No. 17 5523
inhibition and DNA cleavage) of 40 and 20–40 mM
(Figure 2). Ideally, both genetic and biochemical
approaches should be applied in establishing whether
gyrase or topo IV is a cellular target.
Biochemical analysis showed that CL-induced DNA
cleavage by gyrase occurred at speciﬁc sites that partially
overlapped the cleavage repertoire seen for the quinolone
gemiﬂoxacin (Figures 3–5). Scrutiny of many CL sites
TOPA BOTTOM
Clerocidin Gemi
− + + + + − + + + + − + + + + − + + + +Piperidine
T G
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S  E  T             S  E T
Clerocidin Gemi
1 2 3 4 5 6 7 8 9 10 11 12A C G T G
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S   E  T              S   E  T
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Figure 4. CL induces DNA modiﬁcation and irreversible/reversible DNA breakage at gyrase cleavage sites. (A) Probing CL modiﬁcation and
cleavage reversibility. The S fragment, 33P-labelled at the 50 end of the TOP or BOTTOM strand, was incubated with S. pneumoniae gyrase and
1mM ATP (lanes 2–12) in the absence (lane 2) or presence of 200mM CL (lanes 3–7) or 100 mM gemiﬂoxacin (lanes 8–12). Samples in lanes 5 and 10,
6 and 11 and 7 and 12 were further incubated with 0.6MNaCl for 15min (denoted by S), with 35mM EDTA for 15min (E), or heating to 658C for
15min (T), respectively. After cleavage induction with SDS and proteinase K, DNA was precipitated with ethanol. Cleavage products in lanes 4–7
and 9–12 were further incubated with 1-M piperidine at 908C for 30min and then lyophilized. Reaction products were loaded and run on 6%
denaturing polyacrylamide gels alongside the G+A Maxam–Gilbert chemical sequencing products, and the ACGT dideoxy sequencing products
obtained using the same 50 end-labelled oligonucleotide primers. Lane 1 is untreated substrate DNA. Lane 2 is a control for gyrase-processed DNA.
Lanes 3 and 8 are cleavage products that were not treated with piperidine. DNA cleavage products that undergo shortening after hot piperidine are
denoted by ﬁlled circles; those unaﬀected by piperidine are labelled with open circles. Gemiﬂoxacin cleavage products were uniformly unaﬀected by
hot piperidine (compare lanes 8 and 9) and were formed reversibly (lanes 10–12). Several new bands appearing after EDTA treatment (TOP strand,
lane 6) may arise from sealing of sites proximal to the 50 end revealing distal cleavage sites. (B) Mapping CL-gyrase cleavage sites in the S fragment.
Arrowheads and arrows show cleavage sites stimulated by CL and gemiﬂoxacin, respectively. Filled and open arrowheads denote sites of irreversible
and reversible cleavage, respectively. Filled and open circles denote CL sites at which the 30 nucleotide was released by hot piperidine or was wholly
(or partially) unaﬀected by piperidine treatment, respectively. The large arrowheads and circles denote the most eﬃcient cleavage site. Diﬀerent to the
4-bp gyrase stagger, two sites with an apparent 2-bp overhang likely arise from closely spaced single cuts. Numbers refer to nucleotide positions in
the S. pneumoniae parE gene (31) counting from the ﬁrst nucleotide of the initiation codon ATG. Horizontal arrows denote the sequences of forward
(S6398) and reverse oligonucleotides (S6399) used in PCR.
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revealed a very strong preference for G at 1 on one, or
both, strands (Table 1). Mutagenesis of the strong
pBR322 1073 site showed that substitution of both 1G
positions with A, C or T abolished CL-promoted DNA
breakage (Figure 6). We also conducted parallel mutagen-
esis on the well-characterized E site for S. pneumoniae
topo IV (31) and examined double-stranded cleavage of
256-bp E-site PCR products on native agarose gels. We
found that replacement of the two WT 1T nucleotides
with G induced strong double-stranded CL-topo IV clea-
vage, which was absent for 1A, 1C and 1T (Pan, X.S.
and Fisher,L.M., unpublished data). Thus, CL requires at
least one 1 guanine to induce DNA breakage by gyrase
and topo IV.
Perhaps the most surprising and novel ﬁnding of the
present study was that CL reacts diﬀerently with the two
halves of the gyrase-DNA gate (Figures 4 and 5). Previous
studies have reported irreversible and reversible CL-
mediated single-strand cleavage by mammalian topo II
at G and C, respectively, and have alluded to DNA cleav-
age products with abnormal electrophoretic mobility (4).
However, the link between DNA modiﬁcation and (ir)re-
versibility has not been explored. Our analysis of 19 gyrase
sites revealed the same consistent feature of quanti-
tative guanine modiﬁcation and irreversible cleavage
on one strand, accompanied on the complementary
strand by wholly reversible cleavage at an apparently
unmodiﬁed 1A, C or T nucleotide, and variable but
site-reproducible modiﬁcation-reversibility at 1G
(Figures 4–6). These results are the ﬁrst to show diﬀeren-
tial reaction of CL at the two 1 nt of a topoisomerase-
DNA complex.
We have reported that CL-induced DNA damage by
S. pneumoniae topo IV could not be reversed by heat or
salt (i.e. similar to gyrase, Figures 4 and 5) nor by EDTA
(unlike partial EDTA reversal seen for gyrase) implying
that CL induces exclusively irreversible DNA breaks with
topo IV (22). In light of the unusual pattern of CL action
at gyrase sites, we have re-examined and repeated the ear-
lier EDTA reversal work. In those experiments, super-
coiled pBR322 DNA was reacted with 50 mM CL and
topo IV producing nicked circles (30% of total DNA),
full-length linear DNA (one double-strand break per plas-
mid) (40%) and the remainder a smear of smaller linear
DNA species (arising from two or more double-stranded
breaks per plasmid). EDTA reversal caused no detectable
recovery of supercoiled DNA that would arise from seal-
ing of nicked circles or full sealing of a double-stranded
DNA break (hence our conclusion of irreversible DNA
damage). However, EDTA did promote an increase in
nicked DNA that on closer scrutiny arises from depletion
of the smear of linear DNA species. This latter aspect was
missed originally and can only be explained by irreversible
and reversible scission at each topo IV site such that
EDTA converts double-stranded DNA breaks into
DNA nicks allowing recovery of linear and multiply
nicked circular DNA, but not the supercoiled DNA sub-
strate. (The same behaviour was also seen for EDTA
reversal of CL-induced cleavage of pBR322 by gyrase.)
Unfortunately, the assay with plasmid DNA does not
allow examination of particular topo IV sites. However,
by using end-labelled S- and pBR322-fragments as sub-
strates with product analysis on sequencing gels, we
have found that CL-induced topo IV cleavage does gen-
erate piperidine-shifted and -unshifted DNA fragments,
which would correspond to irreversible and reversible
sites (Pan,X.S. and Fisher,L.M., unpublished data).
Evidently, diﬀerential reactivity of the two halves of the
topoisomerase-DNA gate also occurs with topo IV and
thus does not require DNA wrapping in the enzyme
complex.
Our results showing covalent modiﬁcation of gyrase (and
topo IV) cleavage complexes support and extend the earlier
model of CL action against topo II (6). We suggest that CL
ﬁrst binds preferentially and reversibly to gyrase–DNA
complexes in which at least one 1 position is occupied
by guanine. After transient gate opening by gyrase to
form the cleavage complex, the guanine is potentiated for
attack (10). CL is not able to alkylate the canonical B form
of double-stranded DNA for steric reasons (6) and thus the
DNAmust be signiﬁcantly distorted or cleaved to allowCL
attack from themajor groove. N-7modiﬁcation of the1G
is then suﬃcient to block religation perhaps by mis-posi-
tioning the 30OH end. Resealing of the complementary
DNA strand might also be impeded by this guanine mod-
iﬁcation (‘one-drug’ mechanism) or might arise from non-
covalent interactions with a second bound CL molecule
(‘two-drug’ mechanism).
S6398
1178 AAGGCGCGTG ATGAGAGCCG AAATGGGAAG AAAAACAAGA AAGATAAGGG 
TTCCGCGCAC TACTCTCGGC TTTACCCTTC TTTTTGTTCT TTCTATTCCC
CTTGTTGTCT GGGAAATTGA CCCCAGCCCA ATCTAAGAAT CCTGCTAAGA
GAACAACAGA CCCTTTAACT GGGGTCGGGT TAGATTCTTA GGACGATTCT
ATGAACTCTA TCTAGTTGAG GGGGACTCTG CCGGTGGTTC TGCCAAACAA
TACTTGAGAT AGATCAACTC CCCCTGAGAC GGCCACCAAG ACGGTTTGTT
GGTCGTGACC GCAAGTTCCA GGCTATTCTA CCTCTTCGTG GTAAGGTTAT
CCAGCACTGG CGTTCAAGGT CCGATAAGAT GGAGAAGCAC CATTCCAATA
CAATACAGCC AAGGCCAAGA TGGCGGATAT CCTCAAAAAT GAAGAGATCA
GTTATGTCGG TTCCGGTTCT ACCGCCTATA GGAGTTTTTA CTTCTCTAGT
ATACCATGAT TTATACCATT GGTGCGGGTG TTGGAGCAGA   1468
TATGGTACTA AATATGGTAA CCTCGCCCAC AACCTCGTCT
S6399
B
Figure 4. Continued.
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It seems likely that the alkylated guanine is stably
retained in the gyrase complex as suggested by the exact
co-migration of CL-stimulated DNA fragments with
their quinolone- or dideoxy-generated counterparts
(Figures 3–6). Alternatively, the modiﬁed guanine may
have been lost (prior to or post DNA-gate opening) (as
seen for CL attack on free 20 deoxyguanosine) (7) produ-
cing DNA fragments with an abasic site at the 30 end, and
which are reported to have retarded electrophoretic mobi-
lity (38). It is known that an engineered abasic site at the1
position (replacing G) induces E. coli topo IV-mediated
cleavage and that salt, but not EDTA, can reverse abasic
site-induced topo IV cleavage complexes (39). However,
arguing against abasic sites, we found that neither salt,
EDTA, nor heat was able to reverse gyrase cleavage at
the CL-modiﬁed 1 position (Figures 4–6).
Several observations bear on the model. First, simple
epoxides do not induce DNA cleavage by gyrase
(Pan,X.S. and Fisher,L.M., unpublished data) suggesting
that capture of gyrase–DNA complexes by CL involves
Clerocidin Gm
− + + + + − + + + +− + piperidine
TGCA21 4 5 6 7 8 93 4 5 6 73
TOP BOTTOM
Clerocidin
G
+A
S   E   TS   E  T
G
+A TGCA21 G
+A
A
Figure 5. CL-stimulated gyrase cleavage at the pBR322 ‘1073’ site. (A) DNA modiﬁcation and EDTA reversal. A 234-bp pBR322 fragment
(nucleotides 966–1200), labelled with 33P at the 50 end of the TOP or BOTTOM strand, was incubated with gyrase and 1mM ATP in the absence
(lane 2) or presence of 200mM CL (lanes 3–7) or 100mM gemiﬂoxacin (Gm) (lanes 8 and 9). Samples in lanes 5–7 were further incubated with NaCl
(S), EDTA (E) or at 658C (T) as described in the Figure 4 legend. After treatment with SDS and proteinase K, reaction products were precipitated
with ethanol. Samples in lanes 4–7 and 9 were incubated with hot piperidine. Samples were lyophilized and run on 6% denaturing polyacrylamide
gels alongside G+A chemical sequencing and ACGT chain termination sequencing products. Lanes 1 and 2 are controls for untreated DNA and
gyrase processed DNA, respectively. Lanes 3 and 8 are non-piperidine treated cleavage products. The main cleavage site at 1073 produced CL-
stabilized fragments indicated by a ﬁlled circle (TOP strand, piperidine-shifted and irreversible) and by an unﬁlled circle (BOTTOM strand, largely
unshifted by piperidine and EDTA reversible). (B) Location of DNA gyrase cleavage sites in the pBR322 fragment. Symbols are used as described in
the Figure 4B legend. Large arrowheads denote the ‘1073’ site; smaller arrowheads indicate weaker sites. Nucleotide sequence from ref 30.
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speciﬁc binding interactions, e.g. with the diterpenoid ring
as shown for topo IV (22). Second, CL was inactive against
a mutant topo IV unable to form a cleavage complex
implying that gate opening is required for drug action
(22). Indeed, increased access to the enzyme–DNA gate
could underlie ATP-independent cleavage of supercoiled
plasmid (Figure 2) but ATP-dependent breakage of
linear DNA (Figure 3) involving either enhanced
enzyme–DNA aﬃnity or ATP-driven cycling of the
enzyme complex. Third, like CL, quinolones such as gemi-
ﬂoxacin also exhibit a preference (among several determi-
nants) for 1G (31,40) explaining the partial overlap in
gyrase cleavage sites for the two drug classes. Fourth, CL
modiﬁcation of one 1G and (for some sites) low-level
modiﬁcation of the other 1G (Figures 4–6) could imply
a two-drug mechanism. Attack at one guanine to generate
a bulky adduct may inhibit reaction with the other, or
could reﬂect sequence-dependent diﬀerences in guanine
reactivities (38).
The novel gyrA (G79A) alteration blocks CL-stimulated
DNA cleavage (Figure 7B) and is the ﬁrst mutation to be
identiﬁed with CL resistance in vivo, though earlier work
had indirectly linked gyrA with CL resistance in E. coli (2).
G79 is highly conserved throughout type II topoisome-
rases and is located between the a3 and a4 helices of a
CAP-like motif that forms the GyrA DNA breakage-
reunion domain (31). We suggest that G79 of GyrA, the
1 guanine at the DNA gate, and the reactive epoxide
moiety of CL lie together in the ternary complex, and
that mutation of G79 blocks CL binding.
Interestingly, the phenotypes of the various mutants
involving GyrA G79/S81 and ParC S79 (Figure 7 and
Results section) may explain earlier work reporting
cross-resistance of CL and quinolones in E. coli yet
CL activity against quinolone-resistant S. aureus (2).
Mutation of the conserved E. coli GyrA G81 (equivalent
to S. pneumoniae GyrA G79) to aspartate (GGT to
GAT) could be obtained in a single-step to produce the
observed cross-resistance (Figure 7D). However, the same
S. pneumoniae GyrA alteration (G79D, GGG to GAT or
GAC) requires 2 nt changes and would not be recovered in
our single-step mutant selection. Similarly, S. pneumoniae
GyrA S81 (and ParC S79) are conserved in S. aureus (as
GyrA S84 and GrlA S80) and their mutation is often
implicated in quinolone resistance of both species
(25,29,37,41). That the common quinolone-resistance
mutations at these residues do not reduce CL activity
(see Results section, Figure 7 and ref. 22) explains the
lack of cross-resistance in S. aureus. An attractive ratio-
nale binding together these various ﬁndings is that diﬀer-
ent gyrase poisons occupy diﬀerent, perhaps overlapping
sites at the DNA–enzyme interface that are impacted dif-
ferently by neighbouring side-chain mutations.
In summary, we have shown that CL is an unusual inhib-
itor of bacterial type II topoisomerases that exerts its
potent anti-Gram-positive antibacterial activity by diﬀer-
entially modifying the two halves of the gyrase–DNA gate.
901 ACGTTTCGGC GAGAAGCAGG CCATTATCGC CGGCATGGCG GCCGACGCGC TGGGCTACGT 
TGCAAAGCCG CTCTTCGTCC GGTAATAGCG GCCGTACCGC CGGCTGCGCG ACCCGATGCA
961 CTTGCTGGCG TTCGCGACGC GAGGCTGGAT GGCCTTCCCC ATTATGATTC TTCTCGCTTC
GAACGACCGC AAGCGCTGCG CTCCGACCTA CCGGAAGGGG TAATACTAAG AAGAGCGAAG
1021 CGGCGGCATC GGGATGCCCG CGTTGCAGGC CATGCTGTCC AGGCAGGTAG ATGACGACCA
GCCGCCGTAG CCCTACGGGC GCAACGTCCG GTACGACAGG TCCGTCCATC TACTGCTGGT
1081 TCAGGGACAG CTTCAAGGAT CGCTCGCGGC TCTTACCAGC CTAACTTCGA TCATTGGACC
AGTCCCTGTC GAAGTTCCTA GCGAGCGCCG AGAATGGTCG GATTGAAGCT AGTAACCTGG
1141 GCTGATCGTC ACGGCGATTT ATGCCGCCTC GGCGAGCACA TGGAACGGGT TGGCATGGAT
CGACTAGCAG TGCCGCTAAA TACGGCGGAG CCGCTCGTGT ACCTTGCCCA ACCGTACCTA
pBR905
pBR1200
B
Figure 5. Continued.
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Figure 6. Substitution of 1 guanines at the pBR322 ‘1073 site’ with
adenine, cytosine or thymine abolishes gyrase DNA cleavage stimulated
by CL but not by gemiﬂoxacin. The 295-bp pBR322 fragment 50 33P-
labelled on the bottom strand was ampliﬁed by PCR from pBR322
plasmids carrying the wild-type site (G at both 1 positions, indicated
by WT) or mutant sites bearing A, C or T at both 1 positions
(denoted by 1A, 1C and 1T). The fragments were used in a
DNA cleavage assay with gyrase and 1mM ATP and either 100mM
gemiﬂoxacin (lanes 1) or 200mM CL (lanes 2 and 3). DNA was recov-
ered by ethanol precipitation and run on an 6% denaturing polyacry-
lamide gel alongside ACGT chain termination DNA sequencing
products obtained from a wild-type DNA template and G+A
Maxam–Gilbert chemical sequencing products generated for each of
the four substrates. Prior to electrophoresis, one set of CL cleavage
products was treated with hot piperidine (lanes 3). Open circle denotes
cleavage product derived from the major cleavage site.
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That CL reacts with similar 1G speciﬁcity and selectivity
against gyrase and topo IV suggests that both enzymes
bind DNA in a distorted conformation. Precise under-
standing of these enzyme–DNA interactions awaits suc-
cessful X-ray structure studies.
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